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Abstract
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder caused by a genetic
defect in alpha-L-iduronidase (IDUA) which is involved in the degradation of dermatan and heparan sulfates. The
disease has severe and milder phenotypic subtypes. The aim of this study was the detection of mutations in the
IDUA gene from 12 additional MPS I patients with various clinical phenotypes (severe, 8 cases; intermediate, 3
cases; mild, 1 case).
Patients and methods: In this study, the IDUA mutations in eight unrelated Tunisian families were performed by
amplifying and sequencing the IDUA exons and intron-exon jonctions.
Results: Five IDUA mutations were detected: one is the L578Q, a novel mutation found, in milder patient. The
others were the previously described: P533R, Y581X, F602X and R628X that produce a severe and intermediate
phenotype. In addition, eighteen variants, including eight previously unreported polymorphisms (IVS6+21c > a, IVS7
+79c > t, IVS7-45 g > c, IVS9+36t > c, IVS10+140c > a, IVS11+33c > t, IVS12+13c > t and IVS12-31c > g), were
detected.
Conclusion: This paper, showed a heterogeneous pattern of mutations and polymorphisms among Tunisian
patients.
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Background
Mucopolysaccharidosis type I (MPS I) is an autosomal
recessive lysosomal storage disorder that results from a
deficiency in the alpha-L-iduronidase (IDUA; E.
C.3.2.1.76). This glycosidase is involved in the degrada-
tion of dermatan and heparan sulfates. IDUA deficiency
causes a progressive accumulation of undegraded muco-
polysaccharides leading to characterized clinical pheno-
types [1]. MPS I has three major clinical phenotypes,
ranging from the severe Hurler form to the Scheie
phenotype:
The severe phenotype (Hurler syndrome, MPS IH)
involves mental retardation, skeletal of deformities, stiff
joints, hepatosplenomegaly, corneal clouding, and a
shortened life expectancy. The attenuated phenotype
(Scheie syndrome, MPS IS) is characterized by mild ske-
letal deformities, stiff joints, corneal clouding and a long
life span without mental retardation. The intermediate
phenotype (Hurler / Scheie syndrome, MPS IH/S)
involves skeletal deformities, severe organomegaly,
usually limited bone involvement and a variable life
span with neurological involvement. The wide spectrum
of clinical severity in MPS I suggests the presence of
allelic heterogeneity.
The IDUA gene is located on chromosome 4p16.3. It
contains 14 exons spanning 19 kb. It is transcribed into
2.3 kb cDNA, which encodes a 653 amino acids protein
[2,3]. Human Gene Mutation Database described more
than 100 mutations and 32 polymorphisms (http://www.
hgmd.org). Previous mutations including missense and
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severe phenotype. The others gender such as nonsense,
insertion-deletion and splice site have been identified in
both severe and mild phenotypes.
In Tunisia, first cousin inbreeding is the most repre-
sented with an estimated incidence about 32% [4].
Furthermore, Tunisian population is characterized by a
heterogeneous genotype resulting from social assets cre-
ated by invasions and migrations. For example, it exists a
large mutations spectrum of hemoglobinopathies such as
beta-thalassemia identified as a result of rare alleles selec-
tion [5]. Thus, screening IDUA mutation in MPS I
patients is essential to identify the specific mutation of our
country, to detect heterozygote and prenatal diagnosis.
In this study, we investigated IDUA mutation in MPS
I Tunisian families based on a complete scan of IDUA
gene.
Patients and methods
Patients
We studied the mutations in 8 unrelated families (Table
four). All patients were of central and southern Tunisia
origin. The patients were all offspring of consanguineous
mating (Figure 1). A total of 24 alleles were investigated.
Diagnoses were confirmed by demonstration of defi-
ciency IDUA activity in leukocytes. The clinical evalua-
tion of the patients included complete medical history,
physical examination routine haematological and bio-
chemical tests and measurement of leukocytes IDUA
activities. Patients were assigned to one of three clinical
phenotypes according to prior descriptions: 8 severe, 3
intermediate and 1 mild.
Patients of family 1
This family gave birth for 6 patients. Three were died
before our investigation at on age of one year, one year
and 3 months and 12 years. The other three patients:
the first boy was diagnosed at the age of three months
when he was operated for inguinal hernia. Coarse facial
feature were noted at an age of eight months. At the
age of 5 years he developed deafness and chronic otitis.
Then, he deceased as a result of pulmonary and cardiac
deficiency. His brother developed similar coarse facial
features at the age of fifteen months. He showed severe
developmental delay, hydrocephaly, deafness and ingu-
inal hernia. He deceased at the age of sixteen months.
These two patients presented the classical severe phe-
notype of Hurler disease accentuated in the second boy.
Their sister was diagnosed at the age of nine months.
She developed facial dysmorphism, skeletal dysplasia.
This family has beneficiated a prenatal diagnosis.
Patients of family 2
The two boys are developed the same severe phenotype:
facial dysmorphisms, severe skeletal abnormality, cornea
clouding, umbilical hernia and severe mental
retardation.
Patients of family 3
The two patients were a boy of sixteen years old and his
sister of thirteen years old. The boy was characterized
by corneal clouding, moderate skeletal abnormalities,
moderate joint stiffness and valgus deformity. His sister
had very moderate facial dysmorphisms. She was fortui-
tously identified at the age of five years old during our
survey. The clinical features of these two patients were
markedly more moderate than the other Hurler affected
children, demonstrating the Hurler / Scheie phenotype.
The patient deceased at the age of twenty five years old;
however his sister is still survived.
Patient of family 4
The patient had gradually developed a facial dysmorph-
ism, moderate skeletal abnormalities and short status.
He presented the Hurler / Scheie phenotype. Despite
their phenotype, he carried on a normal school
education.
Patient of family 5
The girl was diagnosed at the age of one year. She pre-
sented progressively a severe mental retardation, short
status, umbilical hernia, spacing and shape teeth,
enlarged tonsils, facial dysmorphism, corneal clouding
and dysostosis multiplex. She was a black girl with pig-
mented skin. She deceased at the age of five years old.
She presented the severe Hurler phenotype.
Patients of family 6
T h eg i r lw a sd i a g n o s e da tt h ea g eo ff i v ey e a r s .S h eh a d
developed facial dysmorphism, severe mental retarda-
tion, and hepatomegaly. She deceased at eight years old
as a result of pulmonary and cardiac deficiency.
Patient of family 7
She was diagnosed at the age of one year. She had
developed gradually a facial dysmorphism, scaphoce-
phaly, umbilical hernia. Her intelligence was normal.
Patients of family 8
T h eg i r lw a sd i a g n o s e da tt h ea g eo fn i n em o n t h s .S h e
presented facial dysmorphism, umbilical hernia and cor-
neal clouding. At the age of four years she had devel-
oped severe skeletal abnormalities, short status and
severe mental retardation. She presented the severe
Hurler phenotype. She deceased at five years old.
IDUA activity
IDUA activity was carried out by colorimetric enzyme
assay using phenyl -a-L-iduronide as a substrate in soni-
cated fresh leukocyte pallets. Results were expressed by
μKat/kg of leukocyte protein. To the method validation
we measured the b-glucuronidase activity using the 4-
methylumbelliferyl b-D-glucuronide. Total protein was
established according Hartree method [6].
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Genomic DNA was extracted from peripheral blood leu-
kocytes using a standard phenol/chloroforme procedure
[7]. Each of 14 exons and flanking intron-exon junctions
was amplified as described previously [3].
Polymerase chain reaction (PCR) was carried out in 50
μl total volume containing 50 ng genomic DNA, 0.2
mmol/L dNTP, 0.8 pmol of each primer, 0.08 mmol/L
MgCl2. We used two types of Taq polymerase: 1.5 U
Hot Start Qiagen Taq (to amplify 4, 5, 6, 7, 8, 9 and 13
   
         
 
                  
                      
                     
Figure 1 Pedigrees of Tunisian MPS I families.
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2 and 3 IDUA exons) and 1.5 U QBiogen Taq (to
amplify 1, 10 and 14 IDUA exons).
Cycling conditions were: 95°C for 3 min, followed by
40 cycles for 30s at 95°C, 30s at 58-65°C, 30s at 72°C
and final extension at 72°C for 7 min.
Successfully amplified PCR products were purified
from excess primers and dNTP using plaques Millipore
[LSKSO 9624 Millipores]. Direct sequencing was per-
formed with a Big Dye termination Kit (Applied Biosys-
tems) in both forward and reverse directions with the
same PCR primers and analyzed on an ABI Prism 3130
×l capillary Array Sequencer (Applied Biosystem).
Results
Clinical features and IDUA activity
The clinical features of each patient and leukocyte
IDUA activities are presented in Table 1. IDUA activ-
i t i e sr a n g e df r o m0t o0 . 0 5μKat/kg of protein. (Normal
values 1.7 ®3.5 μKat/kg of protein).
IDUA mutations analysis
We analyzed the IDUA gene of 12 MPS I patients from
Tunisia. The affected probands in the eight families
proved the presence of eight cases of Hurler phenotype,
two cases of Huler / Scheie phenotype and one case of
Scheie phenotype (Table 2). By direct sequencing of the
IDUA gene, we found four previously reported muta-
tions: F602X, P533R, Y581X and R628X and one novel
mutation: L578Q. All mutations and polymorphisms
were confirmed in the parental DNA.
T h ep r o b a n d so ff a m i l yo n ew e r eh o m o z y g o u sf o r
F602X mutation. The probands of families tow, three, four
and six were homozygous for P533R mutation. The pro-
band of family five was homozygous for R628X mutation.
The proband of family seven was heteroallelic for the
novel mutation L578Q and P533R mutation. The proband
of family eight was homozygous for the Y581X mutation.
Furthermore, we identified eighteen sequence variants,
including eight previously novel polymorphisms. The
reported polymorphisms were: A8A, A20A, H33Q,
R105Q, A314A, N181N, T410T, V454I, R489R and
IVS10+53 g > t. The unreported polymorphisms were:
IVS6+21c > a, IVS7+79c > t, IVS7-45 g > c, IVS9+36t >
c, IVS10+140c > a, IVS11+33c > t, IVS12+13c > t,
IVS12-31c > g (Table 3).
Discussion
MPS I is the most common subtype of mucopolysac-
charidosis with an estimated of about 1.7 in 100. 000
live births for the severe and mild forms [8]. The inci-
dence of MPS I in Tunisia is also high, estimated at
0.63 in 100.000 live births [9]. MPS I patients show a
wide spectrum of clinical phenotype ranging from the
severe Hurler to the attenuated Scheie form [10]. Cur-
rently, over 100 mutations have been reported in
patients with the MPS subtypes (Human Gene Mutation
Database; http://www.hgmd.org).
In our investigation, all patients were born from to
consanguineous marriages between first, second and
third cousins (Figure 1). The molecular analysis of the
MPS I patients in eight Tunisian families, identified
five mutations including a novel mutation: L578Q and
four reported mutations: P533R, Y581X, F602X and
R628X (Figure 2). Of note, the common mutations,
Q70X and W402X in European populations were not
found [11].
Patients 1, 2 and 3 from family one were homozy-
gous for the F602X mutation. This predicts the synth-
esis of a premature chain termination of the IDUA
glycopeptide. These patients have undetectable IDUA
activity. F602X mutation was firstly reported in Tuni-
sian patient as deletion-insertion complex in exon 13
of the IDUA gene [12]. Besides, our study confirmed
the absence of F602X mutation in 50 DNAs of our
normal population.
Table 1 Clinical characteristics of Tunisian MPS I patients
FAMILLES I II III IV V VI VII VIII
Patients 1 2 3 4 5 6 7 8 9 10 11 12
Age 5 years 6
months (died)
1 year 3
month (died)
9
months
9 years
(died)
10
years
25 years
(died)
13
years
10 years 5 years
(died)
8 years
(died)
6 years 5 years
Age of onset 2 months 1 month half 9
months
7
months
8
months
9
months
5 years 1 year 6
months
1 year 5 years 1 year 9
months
Sex Male Male Female Male Male Male Female Male Female Female Female Female
Height (cm) 103 (-1,5 DS) 71 (+1DS) 51
(+1DS)
107
(-3 DS)
118
(-3 DS)
120
(-3 DS)
110
(-3 DS)
115
(-3 DS)
102
(-3DS)
107
(-3DS)
120
(3DS)
120
(3DS)
Weight (Kg) 13 (-2 DS) 12 (+2 DS) 7
(+1DS)
19
(-1 DS)
18 (-
3 DS)
20
(-3DS)
15 (-
1 DS)
19 (-1 DS) 18
(-1 DS)
19
(-1DS)
20
(-3DS)
18
(-1DS)
IDUA activity
(μKat/kg)
0,00 0,00 0,00 0,018 0,018 0,030 nd 0,050 0,020 nd 0.09 0.00
Nd: non determined
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four and six were homozygous for the P533R mutation
in exon 11 of IDUA gene. The P533R missens mutation
was first described in a group of 73 MPS I patient (3%)
[13]. Alif et al 2002 [14] reported a high frequency of
this mutation in a group of 13 MPS I patients from
Morocco (92%). This mutation has been identified also
in 10 MPS I patients (62.5%) from Tunisia [15]. The
P533R mutation has been identified in a group of 27
MPS I patients (11%) from Sicily [16] and not identified
in 3 MPS I patients from Egypt [17].
Some studies of genetic and population background
for different inherited diseases such as Niemann-Pick
[18], metachromatic leukodystrophy [19], Gaucher dis-
ease [20] and mucopolysaccharidosis type I [21] succeed
to distinguish the origin of frequent mutation. Haplo-
type analysis may distinguish whether a relatively com-
mon mutation is resulted from a founder effect or from
Table 2 Genotypes Characteristics of MPS I Tunisians patients
families patients Parental
consanguinity
MPS I
phenotype
Mutations Polymorphisms
I 1 3rd cousins severe A8A, A20A, H33Q, R105Q, A314A
2 F602X/F602X
3
II 4 1st cousins severe P533R/P533R Not tested
5
III 6 1st cousins intermediate P533R/P533R A8A, A20A, H33Q, R105Q, A314A
7
IV 8 3rd cousins intermediate P533R/P533R Not tested
V 9 1st cousins severe R628X/R628X A8A, A20A, H33Q, R105Q, A314A, N181N, T410T, V554I,
IVS6+21c > a, IVS7+79c > t, IVS7-45 g > c, IVS9+36t > c, IVS10+140c > a, IVS11
+33c > t, IVS12+13c > t, IVS12-31c > g
VI 10 1st cousins severe P533R/P533R A8A, A20A, H33Q, R105Q, A314A, N181N, T410T, V554I,
IVS6+21c > a, IVS7+79c > t, IVS7-45 g > c, IVS9+36t > c, IVS10+140c > a, IVS11
+33c > t, IVS12+13c > t, IVS12-31c > g
VII 11 2 nd cousins mild L578Q/P533R A8A, A20A, H33Q, R489R
VIII 12 2nd cousins severe Y581X/Y581X H33Q
Table 3 Table 3 polymorphisms characteristics and position in MPS I Tunisians patient
Nucleotide change cDNA position gDNA position Exon/intron codon/nucleotide change Restriction enzyme References
GCC > GCA 112 606 Exon 1 A8A (+ ) Eco47III [13]
GCG > GCA 148 642 Exon 1 A20A [11]
CAG > CAT 187 681 Exon 1 Q33H (+) Nsp 7524I [13]
CGG > CAG 402 441 Exon 3 R105Q (+) AluNI [2]
AAT > AAC 631 1332 Exon 5 N181N [25]
GCG > GCC 1030 1946 Exon 7 A314A [13]
ACC > ACG 1318 2587 Exon 9 T410T [13]
GTC > ATC 1447 2716 Exon 9 V454I [13]
CGC > TGC 1553 2911 Exon 10 R489R [25]
ccg > cag 887+21 1836 Intron 6 IVS6+21c > a (-) AciI
a
acg > atg 1060+79 2055 Intron 7 IVS7+79c > t
a
agc > acc 1061-45 2039 Intron 7 IVS7-45 g > c
a
ctg > ccg 1487+36 2756 Intron 9 IVS9+36t > c (+) NciI
a
ggg > gtg 1612+53 3052 Intron 10 IVS10+53 g > t [25]
gcg > gag 1612+140 3165 Intron 11 IVS10+140c > a
a
ccc > ctc 1720+33 3318 Intron 11 IVS11+33c > t (-) MspI
a
gcc > gtc 1817+12 3420 Intron 12 IVS12+13c > t (-) Sau96I
a
acc > agc 1819-32 3741 Intron 12 IVS12-31c > g (+) BseYI
a
a: Novel sequence changes described in our patients.
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P533R origin estimation we think that haplotypes analy-
sis will be determined for different MPS I populations.
The patient of family five was homozogous for the
previously reported R628X mutation. This patient had
the severe Hurler phenotype and she deceased at five
years of age. We showed in a previous study that this
patient was probably homozygous for this mutation.
This finding is a confirmation of previous hypothesis
[15].
The patient of family seven was heteroallelic for the
novel L578Q mutation and the previous reported P533R
mutation. This patient had the typical Scheie phenotype.
The P533R mutation resulted in a non conservative sub-
stitution of a neutral proline for a basic arginine and
associated with a low level of residual IDUA enzymatic
activity in CHOK I cells [22]. The novel L578Q muta-
tion presumably also causes a mild instability or con-
serves of function since the patient have the attenuated
phenotype. She goes at school and she had a good note
in scientific subjects. Our study showed that L578Q
mutation is not found in 50 DNAs of normal
population.
The patient of family eight was homozygous for the
previously described Y581X mutation. This patient had
the severe Hurler phenotype and she deceased at five
years of age.
A large number of polymorphisms and non-patho-
genic sequence variants have been described in the
IDUA gene [23,22,24]. The effect of these sequence var-
iants on the IDUA activity has not been clearly defined,
especially when they are associated with specific muta-
tions. However, it has been speculated through struc-
tural effects on IDUA gene that such polymorphisms
may modify the patient clinical phenotype [25,26], parti-
cularly for patients who have missense mutations caus-
ing the Hurler / Scheie and Scheie phenotypes [11]. We
found the same previously described polymorphisms
associated to different phenotypes: Hurler and Hurler /
Scheie form for patients of family one and three.
Besides, the novel polymorphisms were associated to
severe phenotype for patient of family five and six.
Mutations which permit some enzymatic function may
be more susceptible to modulation by variables factors
such as novel combinations of mutant alleles, attenuat-
ing polymorphisms, genetic background, and environ-
mental factor (Tables 2, 4).
Screening of polymorphisms in IDUA gene and deter-
mination of the haplotypes is necessary to search the
origin of mutations within MPS I patients. Individuals
resulting from a common ancestor are likely to have
inherited both copies of the mutated gene and also in
the haplotypes which will be transmitted to descent and
thus rare genotypes are maintained [27].
Further studies in determination of haplotypes within
MPS I patients might help in finding out whether these
haplotypes are associated with the reported mutations
and polymorphisms.
Conclusion
In the present paper, eighteen IDUA sequence variants
have been identified of MPS I Tunisian patients, includ-
ing eight novel polymorphisms. The effect of noncoding
and coding polymorphisms on IDUA expression in the
MPS I patients from Tunisia is unclear leading to
ambiguous correlation genotype / phenotype establish-
ment. Further studies on large number of MPS I
patients and normal population might help in finding
Figure 2 Mutations and polymorphisms of IDUA gene.
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are associated with a specific phenotype.
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